GSK and Vir Biotechnology announce United States government agreement to purchase additional supply of sotrovimab

GSK and Vir Biotechnology announce United States government agreement to purchase additional supply of sotrovimab
GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) announced that the US Government will purchase an additional 600,000 doses of sotrovimab, an investigational monoclonal antibody for the early treatment of COVID-19, enabling further nationwide access to sotrovimab for patients.